바이오로직스 아웃소싱 시장 규모 : 제품, 서비스, 원료, 용도, 최종사용자별, 세계 예측(2023-2032년)

Biologics Outsourcing Market size is poised to expand at 14.1% CAGR from 2023-2032 driven by the increasing focus on R&D collaborations between biopharmaceutical companies and outsourcing partners. The rising complexities of biological drug development and production along with collaborative partnerships are enabling the sharing of specialized expertise, technologies, and resources while facilitating the efficient and timely delivery of high-quality products. Such initiatives are fostering innovations, accelerating product development timelines, and enhancing cost-effectiveness for meeting the evolving demands of the biopharmaceutical field.

Moreover, with the large number of companies striving to optimize their R&D efforts, the industry will gain significant momentum in the forecast period. To cite an instance, in October 2023, biopharmaceutical developer Tanvex BioPharma USA Inc. launched Tanvex CDMO to provide comprehensive biologic contract development and production services to the biopharmaceutical sector.

The overall biologics outsourcing industry is segmented based on product, service, source, application, end-user, and region.

With respect to product, the market size from the vaccines segment is anticipated to witness high demand from 2023-2032 driven by the increasing demand for advanced vaccine development and production services. The rising focus on preventive healthcare worldwide and the increasing incidence of infectious diseases is escalating the demand for efficient and scalable vaccine manufacturing solutions. Moreover, the rapid advancements in biotechnology and the growing emphasis on personalized medicine will further boost the segment growth.

Biologics outsourcing industry is anticipated to foresee immense traction from the blood-related product development application segment through 2032. The widespread prevalence of blood disorders and the growing demand for advanced therapeutic solutions are propelling the need for specialized biologics outsourcing services. Moreover, the growing emphasis on personalized medicine and the development of targeted biologic therapies for various blood-related conditions will also contribute to the increasing adoption of outsourced biologics services.

Regionally, the Asia Pacific biologics outsourcing industry is estimated to record robust growth from 2023-2032 fueled by the expanding pharmaceutical and biotechnology sectors in the region. The surging demand for advanced biological therapies and the rising focus on personalized medicine is fueling the need for specialized outsourcing services. Additionally, the presence of cost-effective manufacturing capabilities and skilled workforce is attracting global biopharmaceutical several companies seeking efficient and high-quality outsourcing solutions, further augmenting the regional industry outlook.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market definition
• 1.2 Base estimates & calculations
• 1.3 Forecast parameters
• 1.4 COVID-19 impact analysis at global level
• 1.5 Data validation
• 1.6 Data Sources
  • 1.6.1 Primary
  • 1.6.2 Secondary
    • 1.6.2.1 Paid sources
    • 1.6.2.2 Public sources

Chapter 2 Executive Summary

• 2.1 Biologics outsourcing industry 360 degree synopsis, 2018 - 2032
  • 2.1.1 Business trends
  • 2.1.2 Regional trends
  • 2.1.3 Product trends
  • 2.1.4 Service trends
  • 2.1.5 Source trends
  • 2.1.6 Application trends
  • 2.1.7 End-user trends

Chapter 3 Biologics Outsourcing Industry Insights

• 3.1 Industry segmentation
• 3.2 Industry landscape, 2018 - 2032 (USD Million)
• 3.3 Industry impact forces
  • 3.3.1 Growth drivers
    • 3.3.1.1 Growing complexity of biologics manufacturing, leading to increased outsourcing services
    • 3.3.1.2 Cost-effectiveness and efficiency offered by CROs and CMOs
    • 3.3.1.3 Technological advantages offered by CROs and CMOs
    • 3.3.1.4 Patent expiry and increasing demand for biologics
    • 3.3.1.5 Increasing investments in advanced manufacturing technologies by CDMOs
    • 3.3.1.6 Increasing regulatory compliance and quality assurance
  • 3.3.2 Industry pitfalls & challenges
    • 3.3.2.1 Varying regulatory requirements across regions
    • 3.3.2.2 Lack of constant innovation to balance technological capabilities against costs
    • 3.3.2.3 Potential for loss of in-house expertise may limit biologics outsourcing
• 3.4 Growth potential analysis
  • 3.4.1 By product
  • 3.4.2 By service
  • 3.4.3 By source
  • 3.4.4 By application
  • 3.4.5 By end-user
• 3.5 COVID- 19 impact analysis
• 3.6 Regulatory landscape
  • 3.6.1 U.S.
  • 3.6.2 Canada
  • 3.6.3 Europe
• 3.7 Technology landscape
• 3.8 Industry ecosystem
• 3.9 Porter's analysis
• 3.10 PESTEL analysis

Chapter 4 Competitive Landscape, 2022

• 4.1 Introduction
  • 4.1.1 Merck & Co. Inc
  • 4.1.2 AbbVie Inc
  • 4.1.3 Thermo Fischer Scientific, Inc.
• 4.2 Company matrix analysis, 2022
• 4.3 Competitive analysis of major market players, 2022
• 4.4 Competitive positioning matrix, 2022
• 4.5 Company market share analysis, 2022
• 4.6 Strategy dashboard, 2022

Chapter 5 Biologics Outsourcing Market, By Product, 2018 - 2032 (USD Million)

• 5.1 Key trends, by product
• 5.2 Antibodies
  • 5.2.1 Monoclonal antibodies
  • 5.2.2 Polyclonal antibodies
  • 5.2.3 Antibody drug conjugates
• 5.3 Vaccines
• 5.4 Cell and gene therapeutics
• 5.5 Recombinant proteins
• 5.6 Blood and blood products
• 5.7 Other biologics

Chapter 6 Biologics Outsourcing Market, By Service, 2018 - 2032 (USD Million)

• 6.1 Key trends, by service
• 6.2 Analytical testing
• 6.3 Process development
• 6.4 Cell development
• 6.5 cGMP manufacturing
• 6.6 Other services

Chapter 7 Biologics Outsourcing Market, By Source, 2018 - 2032 (USD Million)

• 7.1 Key trends, by source
• 7.2 Mammalian
  • 7.2.1 Animals
  • 7.2.2 Human
• 7.3 Microorganisms

Chapter 8 Biologics Outsourcing Market, By Application, 2018 - 2032 (USD Million)

• 8.1 Key trends, by application
• 8.2 Oncology
• 8.3 Immunological disorders
• 8.4 Infectious diseases
• 8.5 Vaccine development
• 8.6 Cell and gene therapy
• 8.7 Blood related product development
• 8.8 Stem cell research
• 8.9 Other applications

Chapter 9 Biologics Outsourcing Market, By End-user, 2018 - 2032 (USD Million)

• 9.1 Key trends, by end-user
• 9.2 Pharmaceutical and biopharmaceutical companies
• 9.3 Biotechnological companies

Chapter 10 Biologics Outsourcing Market, By Region, 2018 - 2032 (USD Million)

• 10.1 Key trends, by region
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 France
  • 10.3.4 Spain
  • 10.3.5 Italy
  • 10.3.6 Switzerland
  • 10.3.7 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 Japan
  • 10.4.2 China
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 Rest of Asia Pacific
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
  • 10.5.3 Rest of Latin America
• 10.6 Middle East & Africa
  • 10.6.1 South Africa
  • 10.6.2 Saudi Arabia
  • 10.6.3 Rest of Middle East & Africa

Chapter 11 Company Profiles

• 11.1 AbbVie Inc.
• 11.2 Thermo Fischer Scientific Inc.
• 11.3 Boehringer Ingelheim International GmbH
• 11.4 Merck & Co., Inc.
• 11.5 Lonza Group AG
• 11.6 Catalent, Inc
• 11.7 Wacker Chemie AG (Wacker Biotech GmbH Plc.)
• 11.8 WuXi AppTec Co., Ltd.
• 11.9 Samsung Biologics Co., Ltd.
• 11.10 AGC Biologics
• 11.11 Scorpius BioManufacturing